Brown Capital Management LLC Has $212.96 Million Holdings in Glaukos Co. (NYSE:GKOS)

Brown Capital Management LLC cut its holdings in Glaukos Co. (NYSE:GKOS - Free Report) by 13.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,634,591 shares of the medical instruments supplier's stock after selling 263,365 shares during the quarter. Glaukos comprises approximately 4.6% of Brown Capital Management LLC's holdings, making the stock its 4th largest position. Brown Capital Management LLC owned about 2.96% of Glaukos worth $212,955,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Values First Advisors Inc. acquired a new position in shares of Glaukos in the 3rd quarter valued at $25,000. GAMMA Investing LLC raised its position in shares of Glaukos by 68.8% during the second quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier's stock worth $141,000 after acquiring an additional 486 shares during the last quarter. Fifth Third Wealth Advisors LLC acquired a new position in Glaukos during the 2nd quarter valued at about $187,000. KBC Group NV boosted its stake in Glaukos by 16.2% in the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier's stock valued at $188,000 after acquiring an additional 201 shares during the last quarter. Finally, Brighton Jones LLC acquired a new stake in shares of Glaukos during the second quarter worth $208,000. 99.04% of the stock is currently owned by institutional investors.

Glaukos Stock Performance

GKOS stock traded down $0.49 during mid-day trading on Thursday, hitting $140.95. The company had a trading volume of 154,191 shares, compared to its average volume of 572,457. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The firm has a market cap of $7.77 billion, a PE ratio of -46.90 and a beta of 1.02. The stock's fifty day moving average price is $131.75 and its two-hundred day moving average price is $123.18. Glaukos Co. has a 12 month low of $59.22 and a 12 month high of $145.84.

Glaukos (NYSE:GKOS - Get Free Report) last issued its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.20. The business had revenue of $96.70 million during the quarter, compared to the consensus estimate of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The firm's revenue was up 23.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.50) EPS. On average, analysts forecast that Glaukos Co. will post -1.96 earnings per share for the current fiscal year.

Analyst Ratings Changes

GKOS has been the subject of a number of research analyst reports. BTIG Research increased their price target on Glaukos from $131.00 to $139.00 and gave the stock a "buy" rating in a report on Wednesday, August 28th. StockNews.com raised shares of Glaukos from a "sell" rating to a "hold" rating in a research report on Monday, October 21st. Stifel Nicolaus raised their target price on shares of Glaukos from $130.00 to $145.00 and gave the company a "buy" rating in a research note on Tuesday, September 3rd. JPMorgan Chase & Co. increased their price target on Glaukos from $130.00 to $145.00 and gave the company an "overweight" rating in a research note on Tuesday, November 5th. Finally, Wells Fargo & Company raised their price objective on shares of Glaukos from $135.00 to $145.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $134.55.

Insider Activity

In other news, Director Gilbert H. Kliman sold 3,000 shares of the firm's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $130.67, for a total transaction of $392,010.00. Following the completion of the transaction, the director now directly owns 32,336 shares in the company, valued at $4,225,345.12. This trade represents a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Joseph E. Gilliam sold 2,275 shares of the business's stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total value of $316,156.75. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares of the company's stock, valued at approximately $14,198,425.93. This trade represents a 2.18 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company's stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.